[go: up one dir, main page]

FR3100819B1 - Production et fonctionnalisation de nanoparticules dérivées du phage T5 et utilisations thérapeutiques - Google Patents

Production et fonctionnalisation de nanoparticules dérivées du phage T5 et utilisations thérapeutiques Download PDF

Info

Publication number
FR3100819B1
FR3100819B1 FR1910305A FR1910305A FR3100819B1 FR 3100819 B1 FR3100819 B1 FR 3100819B1 FR 1910305 A FR1910305 A FR 1910305A FR 1910305 A FR1910305 A FR 1910305A FR 3100819 B1 FR3100819 B1 FR 3100819B1
Authority
FR
France
Prior art keywords
phage
functional fragment
fragment
relates
capsid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1910305A
Other languages
English (en)
Other versions
FR3100819A1 (fr
Inventor
Pascale Boulanger
Emeline Vernhes
Nicolas Ducrot
Cherif Linda Larbi
Karim Benihoud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Paris Saclay
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Paris Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1910305A priority Critical patent/FR3100819B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Paris Sud filed Critical Centre National de la Recherche Scientifique CNRS
Priority to US17/761,403 priority patent/US20230190925A1/en
Priority to JP2022518200A priority patent/JP2022549257A/ja
Priority to CN202080079575.0A priority patent/CN114729375A/zh
Priority to CA3154856A priority patent/CA3154856A1/fr
Priority to PCT/FR2020/051628 priority patent/WO2021053309A1/fr
Priority to EP20785815.0A priority patent/EP4031668A1/fr
Publication of FR3100819A1 publication Critical patent/FR3100819A1/fr
Application granted granted Critical
Publication of FR3100819B1 publication Critical patent/FR3100819B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des capsides de phage T5 dépourvue d’ADN génomique dudit phage et exposant, à sa surface, au moins une protéine de fusion d’intérêt. L’invention concerne en particulier une capside de phage T5 dépourvue d’ADN génomique dudit phage et exposant, à sa surface, au moins une protéine de fusion, ladite protéine de fusion comprenant : - au moins un fragment de peptide ou de protéine ayant au moins 80% d’identité avec un fragment d’une protéine de décoration pb10 ; et - au moins un fragment fonctionnel d’un antigène, ou au moins un fragment fonctionnel d’une toxine, ou au moins un fragment de récepteur, ou au moins un fragment fonctionnel d’un signal d’adressage ou de ciblage ou de transport, ou au moins un fragment fonctionnel d’une enzyme, ou au moins un fragment fonctionnel d’une hormone, ou au moins un fragment fonctionnel d’un anticorps, ou au moins un antigène, ou au moins une toxine, ou au moins un récepteur, ou au moins un signal d’adressage ou de ciblage ou de transport, ou au moins une enzyme, ou au moins une hormone, ou au moins un anticorps, ou une combinaison quelconque de ceux-ci. La présente invention porte également sur les méthodes de production d’une telle capside et sur des vecteurs permettant leur production. L’invention concerne en outre les protéines de fusion d’intérêt exposées sur la capside et les acides nucléiques les codant. L’invention concerne également des nanoparticules comprenant ces capsides fonctionnalisées, des compositions pharmaceutiques comprenant ces nanoparticules et/ou ces capsides fonctionnalisées, ainsi que leurs utilisations thérapeutiques, notamment comme médicament et/ou comme vaccin.
FR1910305A 2019-09-18 2019-09-18 Production et fonctionnalisation de nanoparticules dérivées du phage T5 et utilisations thérapeutiques Active FR3100819B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR1910305A FR3100819B1 (fr) 2019-09-18 2019-09-18 Production et fonctionnalisation de nanoparticules dérivées du phage T5 et utilisations thérapeutiques
JP2022518200A JP2022549257A (ja) 2019-09-18 2020-09-18 ファージｔ５由来ナノ粒子の作製及び機能化並びに治療用途
CN202080079575.0A CN114729375A (zh) 2019-09-18 2020-09-18 源自噬菌体t5的纳米颗粒的生产和功能化以及治疗用途
CA3154856A CA3154856A1 (fr) 2019-09-18 2020-09-18 Production et fonctionnalisation de nanoparticules derivees du phage t5 et utilisations therapeutiques
US17/761,403 US20230190925A1 (en) 2019-09-18 2020-09-18 Production and functionalization of nanoparticles derived from phage t5 and therapeutic uses
PCT/FR2020/051628 WO2021053309A1 (fr) 2019-09-18 2020-09-18 Production et fonctionnalisation de nanoparticules dérivées du phage t5 et utilisations thérapeutiques
EP20785815.0A EP4031668A1 (fr) 2019-09-18 2020-09-18 Production et fonctionnalisation de nanoparticules dérivées du phage t5 et utilisations thérapeutiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1910305A FR3100819B1 (fr) 2019-09-18 2019-09-18 Production et fonctionnalisation de nanoparticules dérivées du phage T5 et utilisations thérapeutiques
FR1910305 2019-09-18

Publications (2)

Publication Number Publication Date
FR3100819A1 FR3100819A1 (fr) 2021-03-19
FR3100819B1 true FR3100819B1 (fr) 2024-04-19

Family

ID=71094391

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1910305A Active FR3100819B1 (fr) 2019-09-18 2019-09-18 Production et fonctionnalisation de nanoparticules dérivées du phage T5 et utilisations thérapeutiques

Country Status (7)

Country Link
US (1) US20230190925A1 (fr)
EP (1) EP4031668A1 (fr)
JP (1) JP2022549257A (fr)
CN (1) CN114729375A (fr)
CA (1) CA3154856A1 (fr)
FR (1) FR3100819B1 (fr)
WO (1) WO2021053309A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118813556B (zh) * 2024-08-20 2025-04-25 武汉轻工大学 一种裂解沙门菌和大肠杆菌的噬菌体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9101550D0 (en) * 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
IT1291913B1 (it) * 1997-05-22 1999-01-21 Angeletti P Ist Richerche Bio Metodo che prevede l'uso di batteriofagi per la rivelazione della presenza di molecole di interesse in campioni biologici
US20060147477A1 (en) * 2002-06-11 2006-07-06 Glaxo Group Limited Immunogenic compositions
WO2012001004A1 (fr) * 2010-07-02 2012-01-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Vaccin à base de fimh contre les infections du système urinaire

Also Published As

Publication number Publication date
CA3154856A1 (fr) 2021-03-25
EP4031668A1 (fr) 2022-07-27
US20230190925A1 (en) 2023-06-22
WO2021053309A1 (fr) 2021-03-25
CN114729375A (zh) 2022-07-08
FR3100819A1 (fr) 2021-03-19
JP2022549257A (ja) 2022-11-24

Similar Documents

Publication Publication Date Title
Subramanian et al. Emerging concepts in the pathogenesis of the Streptococcus pneumoniae: from nasopharyngeal colonizer to intracellular pathogen
Fillon et al. Platelet-activating factor receptor and innate immunity: uptake of gram-positive bacterial cell wall into host cells and cell-specific pathophysiology
Unciti-Broceta et al. Specific cell targeting therapy bypasses drug resistance mechanisms in African trypanosomiasis
Beeram et al. A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer
Kim Pathogenesis of bacterial meningitis: from bacteraemia to neuronal injury
Liu et al. D‐peptides as recognition molecules and therapeutic agents
JP5959589B2 (ja) 免疫調節組成物およびその使用方法
Muthumani et al. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody
Town et al. Characterization of murine immunoglobulin G antibodies against human amyloid-β1–42
Singh et al. Protease responsive nanogels for transcytosis across the blood− brain barrier and intracellular delivery of radiopharmaceuticals to brain tumor cells
Iovino et al. Platelet endothelial cell adhesion molecule-1, a putative receptor for the adhesion of Streptococcus pneumoniae to the vascular endothelium of the blood-brain barrier
Dénes et al. Streptococcus pneumoniae worsens cerebral ischemia via interleukin 1 and platelet glycoprotein Ibα
MA56289B1 (fr) Mutéines d'interleukine-21 et méthodes de traitement
FI3408295T3 (fi) Bispesifisiä vasta-ainekonstrukteja käsittävä farmaseuttinen koostumus
Hurst et al. Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin®)
Tashima Brain cancer chemotherapy through a delivery system across the blood-brain barrier into the brain based on receptor-mediated transcytosis using monoclonal antibody conjugates
Lattar et al. Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis
CA3023118C (fr) Anticorps monoclonaux d'adn ciblant des molecules de point de controle
MA38194B1 (fr) Anticorps anti-ceacam5 et leurs utilisations
MA29459B1 (fr) Vaccins
CA2853734A1 (fr) Procedes et compositions associes a la neutralisation intracellulaire par une igg
Wyatt et al. Nanoparticles containing a combination of a drug and an antibody for the treatment of breast cancer brain metastases
Manthe et al. ICAM‐1‐targeted nanocarriers attenuate endothelial release of soluble ICAM‐1, an inflammatory regulator
Rohrbeck et al. Vimentin mediates uptake of C3 exoenzyme
Bachran et al. Cytolethal distending toxin B as a cell-killing component of tumor-targeted anthrax toxin fusion proteins

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210319

PLFP Fee payment

Year of fee payment: 3

TQ Partial transmission of property

Owner name: UNIVERSITE PARIS-SACLAY, FR

Effective date: 20211221

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (, FR

Effective date: 20211221

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7